Work

KarMMa-2 Cohort 2c: Efficacy and Safety of Idecabtagene Vicleucel in Patients with Clinical High-Risk Multiple Myeloma Due to Inadequate Response to Frontline Autologous Stem Cell Transplantation

Year: 2022

Type: article

Source: Blood

DOI: 10.1182/blood-2022-162615

Authors: Madhav Dhodapkar, Melissa Alsina, Jesus Berdeja, Krina Patel, Ravi Vij, Xavier Leleu, Anna Truppel-Hartmann, Debashree Basudhar, Ethan Thompson, Xirong Zheng, Revathi Ananthakrishnan, Linda Favre-Kontula, Chiara Greggio, Lars Sternas, David Siegel

Institutions: Emory University, Moffitt Cancer Center, Sarah Cannon, The University of Texas MD Anderson Cancer Center, Washington University in St. Louis, Bristol-Myers Squibb (United States), Hackensack University Medical Center

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4310107945

FWCI: 3.115

Cites:

Cited by: 21

Related to: 10